Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index
Simon, A., Wegrowski, Y., Bontemps, Y., & Maquart, F
Key selective action features: No Growth Hormone Receptor Binding: Does not activate GH receptors responsible for IGF-1 stimulation and systemic growth effects Preserved Glucose Metabolism: No impact on blood sugar regulation, insulin sensitivity, or diabetic risk markers No Tissue Growth Effects: Does not promote muscle hypertrophy, organ growth, or cell proliferation pathways Adipose-Specific Targeting: Works primarily through beta-3 adrenergic receptors concentrated in fat tissue No IGF-1 Elevation: Clinical trials confirmed no changes in serum IGF-1 levels at therapeutic doses Isolated Lipolytic Action: Maintains the fat-breaking properties of growth hormone fragment 176-191 without broader effects Selective Mechanism: Structural differences from full-length GH prevent binding to receptors mediating non-fat-related effects Clinical Validation: Human studies in 900+ participants confirmed selective fat metabolism without systemic hormonal changes The following guide provides detailed analysis of AOD-9604 s selective action and why this selectivity matters for safe, targeted fat metabolism
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion
There is no established direct causal link between vitamin B12 and joint pain in medical literature
